A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein

Yi Zhang; Pascal Chaux; Vincent Stroobant; Alexander M M Eggermont; Jurgen Corthals; Bernard Maillère; Kris Thielemans; Marie Marchand; Thierry Boon; Pierre Van Der Bruggen

doi:10.4049/jimmunol.171.1.219

A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein

J Immunol. 2003 Jul 1;171(1):219-25. doi: 10.4049/jimmunol.171.1.219.

Authors

Yi Zhang¹, Pascal Chaux, Vincent Stroobant, Alexander M M Eggermont, Jurgen Corthals, Bernard Maillère, Kris Thielemans, Marie Marchand, Thierry Boon, Pierre Van Der Bruggen

Affiliation

¹ Ludwig Institute for Cancer Research and Cellular Genetics Unit, Université de Louvain, Brussels, Belgium.

PMID: 12817001
DOI: 10.4049/jimmunol.171.1.219

Abstract

"Cancer-germline" genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific Ags, which have been used in therapeutic vaccination trials of cancer patients. MAGE-3 is expressed in 74% of metastatic melanoma and in 50% of carcinomas of esophagus, head and neck, bladder, and lung. We report here the identification of a new MAGE-3 peptide, which is recognized by three different CD4(+) T cell clones isolated from a melanoma patient vaccinated with a MAGE-3 protein. These clones, which express different TCRs, recognize an HLA-DR1 peptide ACYEFLWGPRALVETS, which corresponds to the MAGE-3(267-282) and the MAGE-12(267-282) protein sequences. One of the T cell clones, which expresses LFA-1 at a high level, lysed tumor cells expressing DR1 and MAGE-3. Another of these DR1-restricted CD4(+) clones recognized not only the MAGE-3/12 peptide but also homologous peptides encoded by genes MAGE-1, 2, 4, 6, 10, and 11.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amino Acid Sequence
Antigen Presentation* / genetics
Antigens, Neoplasm / administration & dosage
Antigens, Neoplasm / genetics
Antigens, Neoplasm / immunology
Antigens, Neoplasm / metabolism*
CD4-Positive T-Lymphocytes / immunology
CD4-Positive T-Lymphocytes / metabolism*
CD4-Positive T-Lymphocytes / pathology
Cancer Vaccines / administration & dosage*
Cancer Vaccines / genetics
Cancer Vaccines / immunology*
Cell Line, Transformed
Cell Separation
Cells, Cultured
Clone Cells
HLA-DR1 Antigen / metabolism*
Humans
Injections, Intradermal
Melanoma / immunology*
Melanoma / metabolism
Melanoma / pathology
Melanoma / prevention & control
Melanoma-Specific Antigens
Molecular Sequence Data
Neoplasm Proteins / administration & dosage
Neoplasm Proteins / genetics
Neoplasm Proteins / immunology
Neoplasm Proteins / metabolism*
Peptide Fragments / administration & dosage
Peptide Fragments / genetics
Peptide Fragments / immunology
Peptide Fragments / metabolism*
Proteins / metabolism
Tumor Cells, Cultured
Vaccines, Synthetic / administration & dosage
Vaccines, Synthetic / immunology

Substances

Antigens, Neoplasm
Cancer Vaccines
HLA-DR1 Antigen
MAGEA1 protein, human
MAGEA10 protein, human
MAGEA3 protein, human
MAGEA4 protein, human
MAGEL2 protein, human
Mageb1 protein, mouse
Mageb3 protein, mouse
Magel2 protein, mouse
Melanoma-Specific Antigens
Neoplasm Proteins
Peptide Fragments
Proteins
Vaccines, Synthetic